This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP). The study also aims to identify risk factors for specific Mpox outcomes.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Severe Mpox Lesions
Timeframe: From date of disease onset (first symptom) until date of peak number of lesions and sites recorded (up to 3 months)
Clinical Complications Associated With Mpox
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Number of Hospitalisation Events
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Death
Timeframe: From date of disease onset (first symptom) until date of death related to Mpox (up to 3 months)
Differences in Mpox Lesion Severity (the Clinical Manifestation) in PLWHIV and PrEP Users
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Differences in the Clinical Manifestation of Mpox in PLWHIV and PrEP Users by Site of Lesions
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Differences in the Clinical Manifestation of Mpox in PLWHIV and PrEP Users by Severity Indicators
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Differences in the NEWS2 Score ≥5 (Severity Indicator) in PLWHIV and PrEP Users With Mpox
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Differences in the Drug Treatments of Mpox in PLWHIV and PrEP Users
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Differences in the Drug Treatments for Complications of Mpox in PLWHIV and PrEP Users
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Differences in the First Symptom at Onset of Mpox in PLWHIV and PrEP Users
Timeframe: Mpox onset
Mpox Transmission
Timeframe: Mpox onset
Mpox Transmission Characteristics
Timeframe: Mpox onset
Risk Factors for Mpox Outcomes
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months)
Risk Factors for Mpox Outcomes for PLWHIV
Timeframe: From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death(up to 3 months)